Ellen Burnham
Concepts (513)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Alcoholism | 37 | 2023 | 797 | 7.850 |
Why?
| Bronchoalveolar Lavage Fluid | 22 | 2022 | 633 | 2.360 |
Why?
| Lung | 18 | 2022 | 3645 | 2.100 |
Why?
| Alcohol-Related Disorders | 7 | 2015 | 120 | 2.000 |
Why?
| Respiratory Insufficiency | 6 | 2022 | 293 | 1.660 |
Why?
| Pneumonia | 9 | 2023 | 578 | 1.620 |
Why?
| Cannabis | 4 | 2022 | 340 | 1.550 |
Why?
| Respiratory Mucosa | 4 | 2020 | 249 | 1.540 |
Why?
| Acute Lung Injury | 10 | 2022 | 310 | 1.510 |
Why?
| Ethanol | 11 | 2022 | 727 | 1.490 |
Why?
| Critical Illness | 20 | 2023 | 616 | 1.480 |
Why?
| Sepsis | 5 | 2020 | 491 | 1.220 |
Why?
| Critical Care | 9 | 2021 | 519 | 1.190 |
Why?
| Gene Expression | 3 | 2020 | 1520 | 1.190 |
Why?
| Macrophages, Alveolar | 9 | 2021 | 367 | 1.190 |
Why?
| Intensive Care Units | 17 | 2022 | 594 | 1.170 |
Why?
| Marijuana Smoking | 2 | 2021 | 233 | 1.100 |
Why?
| Cytokines | 8 | 2023 | 1951 | 1.100 |
Why?
| Inflammation Mediators | 4 | 2016 | 528 | 1.020 |
Why?
| Middle Aged | 63 | 2022 | 28659 | 1.010 |
Why?
| Streptococcus pneumoniae | 2 | 2018 | 130 | 1.000 |
Why?
| Pulmonary Fibrosis | 3 | 2022 | 310 | 1.000 |
Why?
| Pulmonary Alveoli | 6 | 2016 | 395 | 0.990 |
Why?
| Central Nervous System Depressants | 2 | 2021 | 115 | 0.980 |
Why?
| Acetates | 2 | 2021 | 109 | 0.970 |
Why?
| Stem Cells | 5 | 2015 | 538 | 0.950 |
Why?
| Mentors | 4 | 2014 | 156 | 0.950 |
Why?
| Substance Withdrawal Syndrome | 4 | 2021 | 185 | 0.930 |
Why?
| Leukocytes, Mononuclear | 3 | 2017 | 495 | 0.920 |
Why?
| Cerebrovascular Circulation | 2 | 2021 | 193 | 0.900 |
Why?
| Adult | 57 | 2022 | 32118 | 0.900 |
Why?
| Lung Diseases | 3 | 2021 | 724 | 0.890 |
Why?
| Humans | 118 | 2023 | 117633 | 0.890 |
Why?
| Hospital Mortality | 6 | 2020 | 853 | 0.890 |
Why?
| Hospitalization | 9 | 2023 | 1774 | 0.870 |
Why?
| Smoking | 8 | 2021 | 1654 | 0.860 |
Why?
| Burnout, Professional | 4 | 2022 | 311 | 0.840 |
Why?
| Thalamus | 2 | 2021 | 104 | 0.810 |
Why?
| Male | 72 | 2022 | 60403 | 0.800 |
Why?
| Behavior | 1 | 2021 | 107 | 0.790 |
Why?
| Noninvasive Ventilation | 1 | 2020 | 31 | 0.790 |
Why?
| Case-Control Studies | 14 | 2022 | 3269 | 0.780 |
Why?
| Female | 73 | 2022 | 63247 | 0.780 |
Why?
| Hallucinogens | 1 | 2021 | 70 | 0.780 |
Why?
| Opioid-Related Disorders | 2 | 2023 | 357 | 0.760 |
Why?
| Cigarette Smoking | 2 | 2020 | 89 | 0.730 |
Why?
| Intubation, Intratracheal | 1 | 2020 | 193 | 0.710 |
Why?
| Glutathione | 5 | 2016 | 329 | 0.710 |
Why?
| RNA, Messenger | 5 | 2020 | 2757 | 0.690 |
Why?
| Pneumonia, Pneumococcal | 1 | 2018 | 38 | 0.690 |
Why?
| Survivors | 6 | 2013 | 423 | 0.690 |
Why?
| Physicians, Women | 1 | 2019 | 52 | 0.690 |
Why?
| Respiration, Artificial | 10 | 2020 | 563 | 0.680 |
Why?
| Antioxidants | 4 | 2016 | 585 | 0.670 |
Why?
| Epithelial Cells | 4 | 2021 | 988 | 0.670 |
Why?
| Tobacco Products | 1 | 2019 | 73 | 0.660 |
Why?
| Toll-Like Receptor 2 | 2 | 2016 | 141 | 0.660 |
Why?
| Xanthine Dehydrogenase | 1 | 2017 | 38 | 0.650 |
Why?
| Bronchoalveolar Lavage | 7 | 2023 | 93 | 0.640 |
Why?
| Biomedical Research | 2 | 2021 | 598 | 0.620 |
Why?
| Organ Dysfunction Scores | 1 | 2016 | 33 | 0.600 |
Why?
| Blood-Air Barrier | 2 | 2008 | 10 | 0.600 |
Why?
| Marijuana Abuse | 1 | 2018 | 220 | 0.580 |
Why?
| Toll-Like Receptor 4 | 2 | 2016 | 366 | 0.570 |
Why?
| Glycerophospholipids | 3 | 2021 | 27 | 0.550 |
Why?
| Azithromycin | 1 | 2015 | 88 | 0.550 |
Why?
| Inflammation | 7 | 2021 | 2538 | 0.530 |
Why?
| Professional Autonomy | 1 | 2013 | 30 | 0.510 |
Why?
| Tomography, X-Ray Computed | 2 | 2014 | 2462 | 0.500 |
Why?
| Radiography, Thoracic | 1 | 2014 | 179 | 0.500 |
Why?
| Research Support as Topic | 2 | 2011 | 122 | 0.480 |
Why?
| Lipopolysaccharides | 5 | 2017 | 903 | 0.470 |
Why?
| Immunity, Innate | 1 | 2018 | 756 | 0.460 |
Why?
| Oxidative Stress | 5 | 2017 | 1253 | 0.460 |
Why?
| Cells, Cultured | 8 | 2018 | 4191 | 0.460 |
Why?
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 1419 | 0.460 |
Why?
| Retrospective Studies | 20 | 2023 | 12331 | 0.450 |
Why?
| Bronchoscopy | 3 | 2023 | 245 | 0.450 |
Why?
| Drugs, Chinese Herbal | 1 | 2012 | 19 | 0.450 |
Why?
| Intensive Care Units, Pediatric | 1 | 2013 | 197 | 0.440 |
Why?
| Venous Thromboembolism | 3 | 2020 | 206 | 0.440 |
Why?
| Academic Medical Centers | 2 | 2014 | 414 | 0.440 |
Why?
| Asthma | 2 | 2022 | 2016 | 0.420 |
Why?
| Burns | 3 | 2022 | 225 | 0.420 |
Why?
| Biomarkers | 13 | 2022 | 3574 | 0.390 |
Why?
| Anti-Bacterial Agents | 2 | 2019 | 1422 | 0.390 |
Why?
| Personnel Selection | 1 | 2011 | 72 | 0.390 |
Why?
| Lymphoid Progenitor Cells | 1 | 2009 | 12 | 0.380 |
Why?
| Gene Expression Regulation | 6 | 2022 | 2527 | 0.380 |
Why?
| Malondialdehyde | 2 | 2021 | 31 | 0.380 |
Why?
| Aged | 25 | 2022 | 20249 | 0.380 |
Why?
| Acetaldehyde | 2 | 2021 | 33 | 0.380 |
Why?
| Personnel Staffing and Scheduling | 1 | 2010 | 85 | 0.380 |
Why?
| Muscular Diseases | 3 | 2017 | 106 | 0.380 |
Why?
| Medical Staff, Hospital | 1 | 2010 | 76 | 0.370 |
Why?
| Pneumococcal Infections | 1 | 2010 | 97 | 0.370 |
Why?
| Cohort Studies | 13 | 2020 | 5112 | 0.370 |
Why?
| Hypnotics and Sedatives | 2 | 2008 | 135 | 0.370 |
Why?
| Multiple Organ Failure | 3 | 2006 | 153 | 0.350 |
Why?
| Pulmonary Embolism | 3 | 2019 | 173 | 0.350 |
Why?
| Anesthesiology | 1 | 2008 | 29 | 0.340 |
Why?
| Smokers | 2 | 2021 | 175 | 0.340 |
Why?
| Epidemics | 2 | 2019 | 66 | 0.340 |
Why?
| Burns, Inhalation | 2 | 2017 | 9 | 0.330 |
Why?
| Airway Extubation | 3 | 2013 | 43 | 0.330 |
Why?
| Sexism | 2 | 2019 | 48 | 0.330 |
Why?
| Toll-Like Receptors | 2 | 2018 | 177 | 0.320 |
Why?
| Endothelial Cells | 4 | 2011 | 660 | 0.320 |
Why?
| Alcohol-Induced Disorders, Nervous System | 1 | 2006 | 6 | 0.320 |
Why?
| Betacoronavirus | 2 | 2020 | 268 | 0.310 |
Why?
| Marijuana Use | 2 | 2022 | 157 | 0.310 |
Why?
| Fibronectins | 1 | 2007 | 110 | 0.310 |
Why?
| APACHE | 4 | 2013 | 62 | 0.300 |
Why?
| Deglutition Disorders | 3 | 2013 | 133 | 0.300 |
Why?
| Multivariate Analysis | 5 | 2023 | 1584 | 0.300 |
Why?
| Tissue Plasminogen Activator | 2 | 2018 | 242 | 0.300 |
Why?
| Risk Factors | 16 | 2020 | 9124 | 0.290 |
Why?
| Attitude of Health Personnel | 1 | 2013 | 1029 | 0.290 |
Why?
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2017 | 157 | 0.290 |
Why?
| Preoperative Care | 1 | 2008 | 323 | 0.290 |
Why?
| Young Adult | 12 | 2019 | 11077 | 0.290 |
Why?
| Immunity, Cellular | 2 | 2018 | 282 | 0.280 |
Why?
| Pediatrics | 1 | 2013 | 1021 | 0.280 |
Why?
| Nutritional Physiological Phenomena | 1 | 2005 | 57 | 0.280 |
Why?
| Quality of Life | 2 | 2013 | 2354 | 0.270 |
Why?
| Patient Acceptance of Health Care | 3 | 2019 | 686 | 0.270 |
Why?
| Pneumonia, Viral | 2 | 2020 | 365 | 0.260 |
Why?
| Coronavirus Infections | 2 | 2020 | 353 | 0.260 |
Why?
| Alcohol Drinking | 4 | 2021 | 711 | 0.260 |
Why?
| Bacterial Proteins | 1 | 2010 | 774 | 0.260 |
Why?
| Anticoagulants | 2 | 2019 | 541 | 0.260 |
Why?
| E-Selectin | 1 | 2004 | 48 | 0.260 |
Why?
| Aged, 80 and over | 10 | 2022 | 6795 | 0.250 |
Why?
| Internship and Residency | 1 | 2013 | 1026 | 0.250 |
Why?
| Shock, Septic | 2 | 2022 | 196 | 0.250 |
Why?
| Dyspnea | 2 | 2019 | 199 | 0.240 |
Why?
| Interferons | 2 | 2016 | 139 | 0.240 |
Why?
| Lung Injury | 2 | 2016 | 211 | 0.240 |
Why?
| Pilot Projects | 4 | 2021 | 1441 | 0.230 |
Why?
| Polyneuropathies | 2 | 2017 | 49 | 0.230 |
Why?
| Interleukin-1beta | 2 | 2017 | 414 | 0.230 |
Why?
| Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2022 | 17 | 0.230 |
Why?
| Smoke Inhalation Injury | 2 | 2012 | 18 | 0.230 |
Why?
| Fibroblasts | 3 | 2013 | 849 | 0.220 |
Why?
| Epithelium | 2 | 2021 | 303 | 0.220 |
Why?
| Delirium | 1 | 2023 | 70 | 0.220 |
Why?
| Administration, Inhalation | 2 | 2021 | 656 | 0.220 |
Why?
| Double-Blind Method | 4 | 2014 | 1695 | 0.220 |
Why?
| Interleukin-8 | 3 | 2018 | 254 | 0.210 |
Why?
| Patient Discharge | 2 | 2018 | 820 | 0.210 |
Why?
| Alcohol Abstinence | 1 | 2021 | 12 | 0.210 |
Why?
| Age Factors | 4 | 2021 | 3223 | 0.210 |
Why?
| United States | 12 | 2022 | 12768 | 0.210 |
Why?
| Critical Care Outcomes | 1 | 2020 | 13 | 0.210 |
Why?
| Status Asthmaticus | 1 | 2020 | 11 | 0.210 |
Why?
| Cell Count | 2 | 2015 | 323 | 0.210 |
Why?
| Dysbiosis | 1 | 2022 | 136 | 0.210 |
Why?
| Pandemics | 4 | 2022 | 1155 | 0.210 |
Why?
| Physicians | 3 | 2022 | 771 | 0.210 |
Why?
| Neutrophils | 3 | 2017 | 1263 | 0.200 |
Why?
| Phagocytosis | 2 | 2014 | 372 | 0.200 |
Why?
| Random Allocation | 1 | 2021 | 385 | 0.200 |
Why?
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 216 | 0.190 |
Why?
| Immunoglobulin A | 1 | 2021 | 171 | 0.190 |
Why?
| Capacity Building | 1 | 2020 | 49 | 0.190 |
Why?
| Permeability | 2 | 2012 | 155 | 0.190 |
Why?
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 351 | 0.190 |
Why?
| von Willebrand Factor | 1 | 2019 | 50 | 0.190 |
Why?
| Comorbidity | 4 | 2020 | 1650 | 0.190 |
Why?
| Career Choice | 2 | 2012 | 209 | 0.190 |
Why?
| Homeostasis | 1 | 2003 | 587 | 0.180 |
Why?
| Chemokines | 2 | 2018 | 230 | 0.180 |
Why?
| Faculty, Medical | 1 | 2022 | 256 | 0.180 |
Why?
| Needs Assessment | 1 | 2021 | 343 | 0.180 |
Why?
| Speech Therapy | 1 | 2019 | 22 | 0.180 |
Why?
| Disaster Planning | 1 | 2020 | 79 | 0.180 |
Why?
| Length of Stay | 4 | 2020 | 1046 | 0.180 |
Why?
| Heparin, Low-Molecular-Weight | 1 | 2018 | 24 | 0.180 |
Why?
| Wounds and Injuries | 1 | 2006 | 833 | 0.180 |
Why?
| Cardiology | 1 | 2022 | 339 | 0.180 |
Why?
| Community-Acquired Infections | 1 | 2020 | 149 | 0.180 |
Why?
| Macrolides | 1 | 2019 | 64 | 0.180 |
Why?
| Vecuronium Bromide | 1 | 2018 | 6 | 0.170 |
Why?
| Atracurium | 1 | 2018 | 13 | 0.170 |
Why?
| Heart Failure, Diastolic | 1 | 2018 | 22 | 0.170 |
Why?
| Endothelium, Vascular | 1 | 2005 | 928 | 0.170 |
Why?
| Animals | 16 | 2022 | 34350 | 0.170 |
Why?
| Heart Failure, Systolic | 1 | 2018 | 25 | 0.170 |
Why?
| Neuromuscular Blocking Agents | 1 | 2018 | 22 | 0.170 |
Why?
| Statistics, Nonparametric | 4 | 2014 | 444 | 0.170 |
Why?
| Brain | 3 | 2021 | 2699 | 0.170 |
Why?
| Occupational Therapy | 1 | 2019 | 70 | 0.170 |
Why?
| Pulmonary Ventilation | 1 | 2018 | 73 | 0.170 |
Why?
| Tobacco | 1 | 2019 | 156 | 0.170 |
Why?
| Cardiologists | 1 | 2018 | 38 | 0.170 |
Why?
| Factor Xa Inhibitors | 1 | 2018 | 137 | 0.160 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2018 | 1194 | 0.160 |
Why?
| Heparin | 1 | 2019 | 225 | 0.160 |
Why?
| Chemokine CCL2 | 1 | 2017 | 128 | 0.160 |
Why?
| Hospitals, University | 2 | 2015 | 189 | 0.160 |
Why?
| Hospitalists | 1 | 2020 | 168 | 0.160 |
Why?
| Societies, Medical | 1 | 2021 | 755 | 0.160 |
Why?
| Tobacco Use | 1 | 2017 | 59 | 0.160 |
Why?
| Apoptosis | 3 | 2014 | 2573 | 0.160 |
Why?
| Treatment Outcome | 9 | 2022 | 9353 | 0.160 |
Why?
| Cystine | 1 | 2016 | 13 | 0.160 |
Why?
| Idiopathic Pulmonary Fibrosis | 1 | 2022 | 398 | 0.160 |
Why?
| Cyclooxygenase 2 | 1 | 2017 | 196 | 0.150 |
Why?
| Transforming Growth Factor beta | 3 | 2022 | 469 | 0.150 |
Why?
| Interleukin-6 | 2 | 2018 | 708 | 0.150 |
Why?
| Interleukin-10 | 1 | 2018 | 321 | 0.150 |
Why?
| Vascular Endothelial Growth Factor A | 3 | 2016 | 507 | 0.150 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 1052 | 0.150 |
Why?
| Teichoic Acids | 1 | 2016 | 12 | 0.150 |
Why?
| Disulfides | 1 | 2016 | 95 | 0.150 |
Why?
| DNA, Bacterial | 1 | 2017 | 303 | 0.150 |
Why?
| Respiratory Tract Diseases | 1 | 2017 | 154 | 0.140 |
Why?
| Physical Therapy Modalities | 1 | 2019 | 288 | 0.140 |
Why?
| Fibrinolytic Agents | 1 | 2018 | 245 | 0.140 |
Why?
| Follow-Up Studies | 3 | 2014 | 4911 | 0.140 |
Why?
| RNA Splicing | 1 | 2017 | 253 | 0.140 |
Why?
| Cannabinoids | 1 | 2017 | 116 | 0.140 |
Why?
| Alternative Splicing | 1 | 2017 | 201 | 0.140 |
Why?
| Prevalence | 2 | 2015 | 2438 | 0.140 |
Why?
| Hospitals | 1 | 2020 | 540 | 0.140 |
Why?
| Proteins | 2 | 2021 | 913 | 0.140 |
Why?
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 85 | 0.140 |
Why?
| Inflammasomes | 1 | 2017 | 122 | 0.140 |
Why?
| Cysteine | 1 | 2016 | 200 | 0.140 |
Why?
| Urinary Bladder | 1 | 2017 | 165 | 0.140 |
Why?
| Patient Selection | 2 | 2023 | 698 | 0.140 |
Why?
| Oxidation-Reduction | 2 | 2016 | 957 | 0.140 |
Why?
| Cholesterol | 1 | 2017 | 391 | 0.140 |
Why?
| Interprofessional Relations | 1 | 2017 | 276 | 0.140 |
Why?
| Acetylcysteine | 1 | 2016 | 146 | 0.140 |
Why?
| Transcriptome | 1 | 2020 | 731 | 0.130 |
Why?
| Signal Transduction | 3 | 2022 | 4824 | 0.130 |
Why?
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2012 | 153 | 0.130 |
Why?
| Third-Party Consent | 1 | 2013 | 9 | 0.130 |
Why?
| Quality Improvement | 1 | 2021 | 940 | 0.130 |
Why?
| Competency-Based Education | 1 | 2014 | 68 | 0.120 |
Why?
| Severity of Illness Index | 5 | 2016 | 2884 | 0.120 |
Why?
| Combined Modality Therapy | 1 | 2017 | 1191 | 0.120 |
Why?
| Atherosclerosis | 1 | 2017 | 314 | 0.120 |
Why?
| Professional Competence | 1 | 2014 | 100 | 0.120 |
Why?
| Growth Differentiation Factor 15 | 1 | 2013 | 32 | 0.120 |
Why?
| Chemokine CCL5 | 1 | 2013 | 52 | 0.120 |
Why?
| Total Lung Capacity | 1 | 2013 | 45 | 0.120 |
Why?
| Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 104 | 0.120 |
Why?
| Reproducibility of Results | 3 | 2019 | 2948 | 0.120 |
Why?
| T-Lymphocyte Subsets | 1 | 2015 | 375 | 0.120 |
Why?
| Disease Progression | 1 | 2020 | 2541 | 0.120 |
Why?
| Pulmonary Diffusing Capacity | 1 | 2013 | 66 | 0.120 |
Why?
| Aging | 2 | 2017 | 1690 | 0.120 |
Why?
| Financial Support | 1 | 2012 | 21 | 0.120 |
Why?
| Interleukin-12 | 1 | 2013 | 109 | 0.120 |
Why?
| Informed Consent | 1 | 2013 | 160 | 0.120 |
Why?
| Speech-Language Pathology | 1 | 2012 | 22 | 0.120 |
Why?
| Logistic Models | 5 | 2017 | 2018 | 0.110 |
Why?
| Lymphatic Vessels | 1 | 2012 | 55 | 0.110 |
Why?
| Transcription, Genetic | 2 | 2010 | 1410 | 0.110 |
Why?
| Vital Capacity | 1 | 2013 | 277 | 0.110 |
Why?
| Magnetic Resonance Imaging | 2 | 2021 | 3214 | 0.110 |
Why?
| Cell Survival | 1 | 2015 | 1104 | 0.110 |
Why?
| Neuregulin-1 | 1 | 2012 | 44 | 0.110 |
Why?
| Pepsin A | 1 | 2011 | 18 | 0.110 |
Why?
| Chemokine CXCL12 | 1 | 2012 | 80 | 0.110 |
Why?
| Ubiquitin | 1 | 2012 | 68 | 0.110 |
Why?
| Phytotherapy | 1 | 2012 | 66 | 0.110 |
Why?
| Prospective Studies | 6 | 2021 | 6422 | 0.110 |
Why?
| Lipid Peroxidation | 1 | 2012 | 157 | 0.110 |
Why?
| Capillaries | 2 | 2009 | 104 | 0.110 |
Why?
| Respiratory Aspiration | 1 | 2011 | 36 | 0.110 |
Why?
| Serotonin | 1 | 2014 | 379 | 0.110 |
Why?
| Microbiota | 1 | 2017 | 538 | 0.100 |
Why?
| Respiratory Function Tests | 1 | 2013 | 596 | 0.100 |
Why?
| Genetic Testing | 1 | 2013 | 383 | 0.100 |
Why?
| Cell- and Tissue-Based Therapy | 1 | 2011 | 50 | 0.100 |
Why?
| MicroRNAs | 1 | 2017 | 631 | 0.100 |
Why?
| Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 858 | 0.100 |
Why?
| Night Care | 1 | 2010 | 5 | 0.100 |
Why?
| Awards and Prizes | 1 | 2011 | 54 | 0.100 |
Why?
| After-Hours Care | 1 | 2010 | 16 | 0.100 |
Why?
| Collagen | 1 | 2012 | 426 | 0.100 |
Why?
| ROC Curve | 2 | 2017 | 499 | 0.100 |
Why?
| Nervous System Diseases | 1 | 2013 | 256 | 0.100 |
Why?
| Organizational Culture | 1 | 2011 | 129 | 0.100 |
Why?
| Autoantibodies | 1 | 2017 | 1292 | 0.100 |
Why?
| Colony-Forming Units Assay | 1 | 2009 | 98 | 0.100 |
Why?
| Cell Differentiation | 2 | 2015 | 1791 | 0.100 |
Why?
| Peer Group | 1 | 2011 | 203 | 0.090 |
Why?
| Focus Groups | 1 | 2011 | 376 | 0.090 |
Why?
| Mice, Inbred C57BL | 5 | 2021 | 5136 | 0.090 |
Why?
| Lung Transplantation | 1 | 2011 | 304 | 0.090 |
Why?
| Bayes Theorem | 2 | 2022 | 305 | 0.090 |
Why?
| Thyrotoxicosis | 1 | 2008 | 6 | 0.090 |
Why?
| Practice Guidelines as Topic | 1 | 2017 | 1524 | 0.090 |
Why?
| Hypertension, Pulmonary | 2 | 2011 | 1703 | 0.090 |
Why?
| Program Development | 1 | 2011 | 372 | 0.090 |
Why?
| Gastroesophageal Reflux | 1 | 2011 | 246 | 0.090 |
Why?
| Technetium Tc 99m Pentetate | 1 | 2008 | 6 | 0.090 |
Why?
| Computers | 1 | 2008 | 67 | 0.090 |
Why?
| Chest Pain | 1 | 2008 | 84 | 0.090 |
Why?
| Burn Units | 2 | 2022 | 24 | 0.090 |
Why?
| Radionuclide Imaging | 1 | 2008 | 137 | 0.090 |
Why?
| Half-Life | 1 | 2008 | 159 | 0.090 |
Why?
| Lung Diseases, Interstitial | 1 | 2012 | 431 | 0.080 |
Why?
| Staphylococcus aureus | 1 | 2011 | 391 | 0.080 |
Why?
| Myeloid Cells | 1 | 2008 | 135 | 0.080 |
Why?
| Schools | 1 | 2011 | 415 | 0.080 |
Why?
| Quality Assurance, Health Care | 1 | 2010 | 355 | 0.080 |
Why?
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 24 | 0.080 |
Why?
| Cocaine-Related Disorders | 1 | 2008 | 109 | 0.080 |
Why?
| Radiopharmaceuticals | 1 | 2008 | 171 | 0.080 |
Why?
| Dose-Response Relationship, Drug | 3 | 2019 | 2106 | 0.080 |
Why?
| Georgia | 2 | 2004 | 57 | 0.080 |
Why?
| Indicators and Reagents | 1 | 2007 | 104 | 0.080 |
Why?
| Respiration Disorders | 1 | 2007 | 68 | 0.080 |
Why?
| Sex Factors | 1 | 2013 | 1918 | 0.080 |
Why?
| Body Fluids | 1 | 2007 | 66 | 0.080 |
Why?
| NIH 3T3 Cells | 1 | 2007 | 133 | 0.080 |
Why?
| Stem Cell Transplantation | 1 | 2008 | 146 | 0.080 |
Why?
| Cell Separation | 3 | 2016 | 309 | 0.080 |
Why?
| Mice | 6 | 2022 | 15537 | 0.080 |
Why?
| Cross-Sectional Studies | 4 | 2022 | 4630 | 0.080 |
Why?
| Patient Readmission | 3 | 2019 | 659 | 0.080 |
Why?
| Thrombocytopenia | 2 | 2019 | 188 | 0.080 |
Why?
| Nursing Staff, Hospital | 1 | 2009 | 150 | 0.080 |
Why?
| Pulmonary Artery | 2 | 2013 | 1073 | 0.080 |
Why?
| Program Evaluation | 1 | 2011 | 870 | 0.080 |
Why?
| Matrix Metalloproteinases | 1 | 2007 | 92 | 0.070 |
Why?
| Propensity Score | 2 | 2017 | 251 | 0.070 |
Why?
| Pneumonia, Bacterial | 1 | 2006 | 106 | 0.070 |
Why?
| Flow Cytometry | 1 | 2009 | 1132 | 0.070 |
Why?
| Research Design | 1 | 2011 | 968 | 0.070 |
Why?
| T-Lymphocytes | 1 | 2013 | 1793 | 0.070 |
Why?
| Adolescent | 6 | 2022 | 18902 | 0.070 |
Why?
| Neoplasms | 1 | 2018 | 2139 | 0.070 |
Why?
| Hemorrhage | 2 | 2019 | 605 | 0.070 |
Why?
| Observation | 1 | 2004 | 57 | 0.060 |
Why?
| Databases, Factual | 2 | 2019 | 1145 | 0.060 |
Why?
| Colorado | 4 | 2022 | 4401 | 0.060 |
Why?
| Dimercaprol | 1 | 2023 | 7 | 0.060 |
Why?
| Surveys and Questionnaires | 2 | 2022 | 4842 | 0.060 |
Why?
| Hydroxyethyl Starch Derivatives | 1 | 2003 | 6 | 0.060 |
Why?
| Nutritional Status | 1 | 2005 | 291 | 0.060 |
Why?
| Body Surface Area | 1 | 2022 | 30 | 0.060 |
Why?
| Time Factors | 4 | 2018 | 6906 | 0.060 |
Why?
| rhoA GTP-Binding Protein | 2 | 2014 | 76 | 0.060 |
Why?
| Phosphoric Monoester Hydrolases | 1 | 2022 | 53 | 0.060 |
Why?
| Receptors, Polymeric Immunoglobulin | 1 | 2021 | 2 | 0.050 |
Why?
| Naltrexone | 1 | 2022 | 90 | 0.050 |
Why?
| North America | 1 | 2022 | 269 | 0.050 |
Why?
| Transcytosis | 1 | 2021 | 9 | 0.050 |
Why?
| rho-Associated Kinases | 2 | 2014 | 84 | 0.050 |
Why?
| Vasoconstrictor Agents | 1 | 2022 | 124 | 0.050 |
Why?
| Blood Alcohol Content | 1 | 2021 | 6 | 0.050 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2009 | 685 | 0.050 |
Why?
| Cilia | 1 | 2022 | 153 | 0.050 |
Why?
| Mice, Knockout | 2 | 2021 | 2805 | 0.050 |
Why?
| Hedgehog Proteins | 1 | 2022 | 173 | 0.050 |
Why?
| Vasopressins | 1 | 2022 | 143 | 0.050 |
Why?
| Norepinephrine | 1 | 2022 | 261 | 0.050 |
Why?
| Ligands | 1 | 2023 | 520 | 0.050 |
Why?
| Bleomycin | 1 | 2022 | 211 | 0.050 |
Why?
| Disease Models, Animal | 3 | 2021 | 3799 | 0.050 |
Why?
| Containment of Biohazards | 1 | 2020 | 10 | 0.050 |
Why?
| Medical Oncology | 1 | 2022 | 221 | 0.050 |
Why?
| Recombinant Proteins | 2 | 2015 | 1322 | 0.050 |
Why?
| Intersectoral Collaboration | 1 | 2020 | 60 | 0.050 |
Why?
| Protein Transport | 1 | 2021 | 425 | 0.050 |
Why?
| Prognosis | 3 | 2013 | 3549 | 0.050 |
Why?
| Incidence | 2 | 2003 | 2504 | 0.050 |
Why?
| Pharmacoepidemiology | 1 | 2019 | 20 | 0.050 |
Why?
| Fellowships and Scholarships | 1 | 2022 | 243 | 0.050 |
Why?
| Chronic Disease | 3 | 2015 | 1674 | 0.050 |
Why?
| Administration, Intravenous | 1 | 2019 | 138 | 0.040 |
Why?
| Leadership | 1 | 2022 | 320 | 0.040 |
Why?
| Hospitals, Rural | 1 | 2018 | 37 | 0.040 |
Why?
| Coronary Circulation | 1 | 2018 | 147 | 0.040 |
Why?
| Illinois | 1 | 2017 | 35 | 0.040 |
Why?
| Hospital Charges | 1 | 2017 | 52 | 0.040 |
Why?
| RNA Transport | 1 | 2017 | 22 | 0.040 |
Why?
| Comparative Effectiveness Research | 1 | 2018 | 140 | 0.040 |
Why?
| Adaptation, Psychological | 1 | 2022 | 596 | 0.040 |
Why?
| Hospitals, Urban | 1 | 2018 | 144 | 0.040 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2017 | 92 | 0.040 |
Why?
| Postoperative Complications | 1 | 2008 | 2113 | 0.040 |
Why?
| Dried Blood Spot Testing | 1 | 2017 | 67 | 0.040 |
Why?
| Venous Thrombosis | 1 | 2019 | 134 | 0.040 |
Why?
| Administration, Oral | 1 | 2019 | 786 | 0.040 |
Why?
| Disease-Free Survival | 1 | 2018 | 678 | 0.040 |
Why?
| Gene Knockdown Techniques | 1 | 2017 | 327 | 0.040 |
Why?
| RNA Precursors | 1 | 2017 | 141 | 0.040 |
Why?
| Sex Distribution | 1 | 2017 | 390 | 0.040 |
Why?
| Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 3 | 0.040 |
Why?
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.040 |
Why?
| Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 36 | 0.040 |
Why?
| Capillary Leak Syndrome | 1 | 2015 | 11 | 0.040 |
Why?
| Cell Communication | 1 | 2017 | 272 | 0.040 |
Why?
| Chromatography, Liquid | 1 | 2017 | 337 | 0.040 |
Why?
| Cause of Death | 1 | 2017 | 399 | 0.040 |
Why?
| Capillary Permeability | 1 | 2016 | 146 | 0.040 |
Why?
| Coculture Techniques | 1 | 2015 | 200 | 0.030 |
Why?
| RNA, Ribosomal, 16S | 1 | 2017 | 483 | 0.030 |
Why?
| Cognition | 1 | 2023 | 1019 | 0.030 |
Why?
| Interferon-alpha | 1 | 2016 | 200 | 0.030 |
Why?
| Ventricular Function, Left | 1 | 2018 | 503 | 0.030 |
Why?
| Delivery of Health Care | 1 | 2022 | 814 | 0.030 |
Why?
| Diet, High-Fat | 1 | 2017 | 267 | 0.030 |
Why?
| Linear Models | 1 | 2017 | 871 | 0.030 |
Why?
| Risk | 1 | 2018 | 926 | 0.030 |
Why?
| Interleukin-4 | 1 | 2015 | 208 | 0.030 |
Why?
| Sequence Analysis, DNA | 1 | 2017 | 706 | 0.030 |
Why?
| Gastrointestinal Tract | 1 | 2016 | 161 | 0.030 |
Why?
| Predictive Value of Tests | 1 | 2019 | 1971 | 0.030 |
Why?
| Phylogeny | 1 | 2017 | 722 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2016 | 896 | 0.030 |
Why?
| Mental Competency | 1 | 2013 | 33 | 0.030 |
Why?
| Catheterization, Swan-Ganz | 1 | 2013 | 8 | 0.030 |
Why?
| Nanoparticles | 1 | 2017 | 320 | 0.030 |
Why?
| Odds Ratio | 1 | 2016 | 1038 | 0.030 |
Why?
| Confidence Intervals | 1 | 2014 | 339 | 0.030 |
Why?
| Ventilator Weaning | 1 | 2013 | 32 | 0.030 |
Why?
| Vascular Endothelial Growth Factor D | 1 | 2012 | 9 | 0.030 |
Why?
| Tidal Volume | 1 | 2013 | 73 | 0.030 |
Why?
| Lymphangiogenesis | 1 | 2012 | 23 | 0.030 |
Why?
| Vascular Endothelial Growth Factor C | 1 | 2012 | 16 | 0.030 |
Why?
| Thymus Gland | 1 | 2014 | 276 | 0.030 |
Why?
| Multicenter Studies as Topic | 1 | 2013 | 232 | 0.030 |
Why?
| Biological Transport | 1 | 2014 | 406 | 0.030 |
Why?
| Survival Analysis | 1 | 2016 | 1358 | 0.030 |
Why?
| Fibrosis | 1 | 2015 | 458 | 0.030 |
Why?
| Healthcare Disparities | 1 | 2018 | 490 | 0.030 |
Why?
| National Institutes of Health (U.S.) | 1 | 2012 | 111 | 0.030 |
Why?
| Fluid Therapy | 1 | 2013 | 151 | 0.030 |
Why?
| Mass Spectrometry | 1 | 2015 | 684 | 0.030 |
Why?
| Observer Variation | 1 | 2012 | 326 | 0.030 |
Why?
| Protein Binding | 1 | 2017 | 2018 | 0.030 |
Why?
| Proteomics | 1 | 2017 | 806 | 0.030 |
Why?
| Lipid Metabolism | 1 | 2015 | 525 | 0.030 |
Why?
| Extracellular Matrix | 1 | 2015 | 422 | 0.030 |
Why?
| Bronchiolitis Obliterans | 1 | 2011 | 71 | 0.030 |
Why?
| Microbial Viability | 1 | 2011 | 79 | 0.030 |
Why?
| Research Personnel | 1 | 2012 | 157 | 0.030 |
Why?
| Infusions, Intravenous | 1 | 2012 | 393 | 0.030 |
Why?
| World Health Organization | 1 | 2011 | 112 | 0.030 |
Why?
| Rats, Sprague-Dawley | 1 | 2017 | 2854 | 0.030 |
Why?
| Superoxides | 1 | 2011 | 230 | 0.030 |
Why?
| Autoimmune Diseases | 1 | 2014 | 409 | 0.020 |
Why?
| Immunomodulation | 1 | 2011 | 87 | 0.020 |
Why?
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 293 | 0.020 |
Why?
| Viruses | 1 | 2011 | 91 | 0.020 |
Why?
| Metabolomics | 1 | 2015 | 537 | 0.020 |
Why?
| rho GTP-Binding Proteins | 1 | 2010 | 67 | 0.020 |
Why?
| Amides | 1 | 2010 | 87 | 0.020 |
Why?
| Blood Pressure | 1 | 2017 | 1680 | 0.020 |
Why?
| Injury Severity Score | 1 | 2012 | 515 | 0.020 |
Why?
| Radiography | 1 | 2012 | 860 | 0.020 |
Why?
| Species Specificity | 1 | 2011 | 594 | 0.020 |
Why?
| Lung Compliance | 1 | 2009 | 53 | 0.020 |
Why?
| Cell Death | 1 | 2011 | 344 | 0.020 |
Why?
| Receptor, ErbB-2 | 1 | 2012 | 318 | 0.020 |
Why?
| Gene Expression Profiling | 1 | 2016 | 1595 | 0.020 |
Why?
| Phosphorylation | 1 | 2014 | 1678 | 0.020 |
Why?
| Endoscopy, Gastrointestinal | 1 | 2011 | 201 | 0.020 |
Why?
| Physician-Nurse Relations | 1 | 2009 | 17 | 0.020 |
Why?
| Mitochondria | 1 | 2015 | 823 | 0.020 |
Why?
| AC133 Antigen | 1 | 2008 | 21 | 0.020 |
Why?
| Leisure Activities | 1 | 2009 | 31 | 0.020 |
Why?
| Cell Fusion | 1 | 2008 | 54 | 0.020 |
Why?
| Biopsy | 1 | 2012 | 1070 | 0.020 |
Why?
| Giant Cells | 1 | 2008 | 23 | 0.020 |
Why?
| Triiodothyronine | 1 | 2008 | 48 | 0.020 |
Why?
| Leukocyte Common Antigens | 1 | 2008 | 78 | 0.020 |
Why?
| Thyroxine | 1 | 2008 | 65 | 0.020 |
Why?
| Nurse Administrators | 1 | 2009 | 42 | 0.020 |
Why?
| Outpatient Clinics, Hospital | 1 | 2009 | 83 | 0.020 |
Why?
| Drug Administration Schedule | 1 | 2010 | 780 | 0.020 |
Why?
| Child | 2 | 2022 | 18649 | 0.020 |
Why?
| Osteocytes | 1 | 2008 | 27 | 0.020 |
Why?
| Breath Tests | 1 | 2007 | 92 | 0.020 |
Why?
| Clone Cells | 1 | 2008 | 244 | 0.020 |
Why?
| Rats | 1 | 2017 | 6016 | 0.020 |
Why?
| Databases as Topic | 1 | 2007 | 60 | 0.020 |
Why?
| Laparoscopy | 1 | 2011 | 395 | 0.020 |
Why?
| Curriculum | 1 | 2014 | 886 | 0.020 |
Why?
| Job Satisfaction | 1 | 2009 | 182 | 0.020 |
Why?
| Health Surveys | 1 | 2009 | 485 | 0.020 |
Why?
| Social Environment | 1 | 2009 | 328 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2012 | 1209 | 0.020 |
Why?
| Glycoproteins | 1 | 2008 | 324 | 0.020 |
Why?
| Cell Movement | 1 | 2011 | 925 | 0.020 |
Why?
| Pyridines | 1 | 2010 | 471 | 0.020 |
Why?
| Adipocytes | 1 | 2008 | 195 | 0.020 |
Why?
| Hydrogen-Ion Concentration | 1 | 2007 | 543 | 0.020 |
Why?
| Models, Biological | 1 | 2014 | 1763 | 0.020 |
Why?
| Antigens, CD | 1 | 2008 | 470 | 0.020 |
Why?
| Hydrogen Peroxide | 1 | 2007 | 298 | 0.020 |
Why?
| Trauma Centers | 1 | 2009 | 395 | 0.020 |
Why?
| Cell Lineage | 1 | 2008 | 350 | 0.020 |
Why?
| Chondrocytes | 1 | 2008 | 210 | 0.020 |
Why?
| Telomerase | 1 | 2008 | 217 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2008 | 1405 | 0.020 |
Why?
| Health Care Costs | 1 | 2007 | 410 | 0.020 |
Why?
| France | 1 | 2003 | 41 | 0.020 |
Why?
| Contraindications | 1 | 2003 | 93 | 0.010 |
Why?
| Hypoxia | 1 | 2009 | 923 | 0.010 |
Why?
| Peptides | 1 | 2008 | 873 | 0.010 |
Why?
| Washington | 1 | 2003 | 129 | 0.010 |
Why?
| Cardiac Output | 1 | 2003 | 155 | 0.010 |
Why?
| Cell Proliferation | 1 | 2008 | 2369 | 0.010 |
Why?
| Analysis of Variance | 1 | 2003 | 1451 | 0.010 |
Why?
|
|
Burnham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|